Tags

Type your tag names separated by a space and hit enter

Comparative in vitro activities of SMT19969, a new antimicrobial agent, against Clostridium difficile and 350 gram-positive and gram-negative aerobic and anaerobic intestinal flora isolates.
Antimicrob Agents Chemother. 2013 Oct; 57(10):4872-6.AA

Abstract

The comparative in vitro activity of SMT19969, a novel, narrow-spectrum, nonabsorbable agent, was studied against 50 ribotype-defined Clostridium difficile strains, 174 Gram-positive and 136 Gram-negative intestinal anaerobes, and 40 Gram-positive aerobes. SMT19969 was one dilution more active against C. difficile isolates (MIC range, 0.125 to 0.5 μg/ml; MIC90, 0.25 μg/ml), including ribotype 027 strains, than fidaxomicin (range, 0.06 to 1 μg/ml; MIC90, 0.5 μg/ml) and two to six dilutions lower than either vancomycin or metronidazole. SMT19969 and fidaxomicin were generally less active against Gram-negative anaerobes, especially the Bacteroides fragilis group species, than vancomycin and metronidazole, suggesting that SMT19969 has a lesser impact on the normal intestinal microbiota that maintain colonization resistance. SMT19969 showed limited activity against other Gram-positive anaerobes, including Bifidobacteria species, Eggerthella lenta, Finegoldia magna, and Peptostreptococcus anaerobius, with MIC90s of >512, >512, 64, and 64 μg/ml, respectively. Clostridium species showed various levels of susceptibility, with C. innocuum being susceptible (MIC90, 1 μg/ml) and C. ramosum and C. perfringens being nonsusceptible (MIC90, >512 μg/ml). Activity against Lactobacillus spp. (range, 0.06 to >512 μg/ml; MIC90, >512 μg/ml) was comparable to that of fidaxomicin and varied by species and strain. Gram-positive aerobic cocci (Staphylococcus aureus, Enterococcus faecalis, E. faecium, and streptococci) showed high SMT19969 MIC90 values (128 to >512 μg/ml).

Authors+Show Affiliations

R. M. Alden Research Laboratory, Culver City, California, USA.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

23877700

Citation

Goldstein, Ellie J C., et al. "Comparative in Vitro Activities of SMT19969, a New Antimicrobial Agent, Against Clostridium Difficile and 350 Gram-positive and Gram-negative Aerobic and Anaerobic Intestinal Flora Isolates." Antimicrobial Agents and Chemotherapy, vol. 57, no. 10, 2013, pp. 4872-6.
Goldstein EJ, Citron DM, Tyrrell KL, et al. Comparative in vitro activities of SMT19969, a new antimicrobial agent, against Clostridium difficile and 350 gram-positive and gram-negative aerobic and anaerobic intestinal flora isolates. Antimicrob Agents Chemother. 2013;57(10):4872-6.
Goldstein, E. J., Citron, D. M., Tyrrell, K. L., & Merriam, C. V. (2013). Comparative in vitro activities of SMT19969, a new antimicrobial agent, against Clostridium difficile and 350 gram-positive and gram-negative aerobic and anaerobic intestinal flora isolates. Antimicrobial Agents and Chemotherapy, 57(10), 4872-6. https://doi.org/10.1128/AAC.01136-13
Goldstein EJ, et al. Comparative in Vitro Activities of SMT19969, a New Antimicrobial Agent, Against Clostridium Difficile and 350 Gram-positive and Gram-negative Aerobic and Anaerobic Intestinal Flora Isolates. Antimicrob Agents Chemother. 2013;57(10):4872-6. PubMed PMID: 23877700.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Comparative in vitro activities of SMT19969, a new antimicrobial agent, against Clostridium difficile and 350 gram-positive and gram-negative aerobic and anaerobic intestinal flora isolates. AU - Goldstein,Ellie J C, AU - Citron,Diane M, AU - Tyrrell,Kerin L, AU - Merriam,C Vreni, Y1 - 2013/07/22/ PY - 2013/7/24/entrez PY - 2013/7/24/pubmed PY - 2014/4/10/medline SP - 4872 EP - 6 JF - Antimicrobial agents and chemotherapy JO - Antimicrob. Agents Chemother. VL - 57 IS - 10 N2 - The comparative in vitro activity of SMT19969, a novel, narrow-spectrum, nonabsorbable agent, was studied against 50 ribotype-defined Clostridium difficile strains, 174 Gram-positive and 136 Gram-negative intestinal anaerobes, and 40 Gram-positive aerobes. SMT19969 was one dilution more active against C. difficile isolates (MIC range, 0.125 to 0.5 μg/ml; MIC90, 0.25 μg/ml), including ribotype 027 strains, than fidaxomicin (range, 0.06 to 1 μg/ml; MIC90, 0.5 μg/ml) and two to six dilutions lower than either vancomycin or metronidazole. SMT19969 and fidaxomicin were generally less active against Gram-negative anaerobes, especially the Bacteroides fragilis group species, than vancomycin and metronidazole, suggesting that SMT19969 has a lesser impact on the normal intestinal microbiota that maintain colonization resistance. SMT19969 showed limited activity against other Gram-positive anaerobes, including Bifidobacteria species, Eggerthella lenta, Finegoldia magna, and Peptostreptococcus anaerobius, with MIC90s of >512, >512, 64, and 64 μg/ml, respectively. Clostridium species showed various levels of susceptibility, with C. innocuum being susceptible (MIC90, 1 μg/ml) and C. ramosum and C. perfringens being nonsusceptible (MIC90, >512 μg/ml). Activity against Lactobacillus spp. (range, 0.06 to >512 μg/ml; MIC90, >512 μg/ml) was comparable to that of fidaxomicin and varied by species and strain. Gram-positive aerobic cocci (Staphylococcus aureus, Enterococcus faecalis, E. faecium, and streptococci) showed high SMT19969 MIC90 values (128 to >512 μg/ml). SN - 1098-6596 UR - https://www.unboundmedicine.com/medline/citation/23877700/Comparative_in_vitro_activities_of_SMT19969_a_new_antimicrobial_agent_against_Clostridium_difficile_and_350_gram_positive_and_gram_negative_aerobic_and_anaerobic_intestinal_flora_isolates_ L2 - http://aac.asm.org/cgi/pmidlookup?view=long&pmid=23877700 DB - PRIME DP - Unbound Medicine ER -